Document is current
Any future updates will be listed below
-
Authors
Najm, Fadi J.
DeWeirdt, Peter https://orcid.org/0000-0002-4707-7940
Moore, Molly M. https://orcid.org/0000-0002-7833-0769
Bevill, Samantha M.
El Farran, Chadi A. https://orcid.org/0000-0002-9374-103X
Macias, Kevin A.
Hegde, Mudra
Waterbury, Amanda L.
Liau, Brian B. https://orcid.org/0000-0002-2985-462X
van Galen, Peter https://orcid.org/0000-0002-0735-1570
Doench, John G. https://orcid.org/0000-0002-3707-9889
Bernstein, Bradley E. https://orcid.org/0000-0002-5726-6278
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5F31CA224536-02, DP1CA216873)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (UM1HG009390)
- License Information
-
More Information
Article History
Received: 19 September 2022
Accepted: 18 January 2023
First Online: 27 January 2023
Competing interests
: B.E.B. declares outside interests in Fulcrum Therapeutics, HiFiBio, Arsenal Biosciences, Cell Signaling Technologies, Chroma Medicine, and Design Pharmaceuticals. J.G.D. consults for Microsoft Research, Abata Therapeutics, Servier, Maze Therapeutics, BioNTech, Sangamo, and Pfizer. J.G.D. consults for and has equity in Tango Therapeutics. J.G.D. serves as a paid scientific advisor to the Laboratory for Genomics Research, funded in part by GlaxoSmithKline. J.G.D. receives funding support from the Functional Genomics Consortium: Abbvie, Bristol Myers Squibb, Janssen, Merck, and Vir Biotechnology. J.G.D.’s interests were reviewed and are managed by the Broad Institute in accordance with its conflict of interest policies. All other authors declare no competing interests.
